India Future Society organized an Online Longevity Conference to raise awareness about Longevity and related research worldwide. The conference was joined by Liz Parrish, Sarah Ahamad, Dr. Ilia Stambler, Dr. Avinash K Singh, and Dr. Alex Zhavoronkov, followed by a panel discussion.
The first speaker was Liz Parrish. Ms. Parrish is the CEO of BioViva-Science, a company predominantly involved in treating ageing genetically. She was the patient zero in her own anti-ageing experiment where she took myostatin inhibitor, which is expected to prevent age-associated muscle loss; and a telomerase gene therapy, which is expected to lengthen telomeres, segments of DNA at the ends of chromosomes whose shortening is associated with aging and degenerative disease. They are researching upon the senescence target genes and studying them for anti-ageing, eg. the Klotho gene which is an anti-ageing and cognition enhancing gene, for research purposes. Human beings have two kinds of aging, one is chronological, and another is biological. Their company currently has a product named TIMEKEEPER™ DNA METHYLATION KIT, which checks the body’s biological age by measuring the amount of methylated DNA in the cell.
The second speaker was Sarah Ahamed. Ms. Ahamed is a Board Member of India Future Society, talks about the status of Longevity Research in India. She talks about the various ongoing government and private research in the field of longevity in India, especially about the Longitidinal ageing Study (LASI) done in collaboration with Harvard University to study patterns and trends in ageing in India, foundation of National Ageing Centre at AIIMS New Delhi, Indi, and changes done in policy making level to understand and combat ageing related issue in India.
The third speaker was Dr. Ilia Stambler. Dr. Stambler is a Chief Science Officer of “Vetek” (Seniority) Association – The Senior Citizens Movement (Israel). Ilia mainly talks about Longevity Movement at policy-making level. He talks about different kinds of ageing, especially mitochondria which plays a crucial role in mediating and amplifying the oxidative stress that drives the aging process. He talks about Longevity history, potential interventions to ameliorate degenerative aging, methodological problems of diagnosing and treating, degenerative aging as a medical condition to extend a healthy lifespan. He focuses on the use of Information Theory for the evaluation of biomarkers of aging, physiological age to predict Aging-related Diseases and frailty and physical means for healthy life extension.
The fourth speaker was Dr. Avinash Singh. Dr. Singh talks about how Brain-Computer Interface technology could transfer to digital longevity. He talks about the limitation and possibilities of existing Brain-Computer Interface and how to apply it for mind-uploading, enabling us to live forever. He also mentioned some of the top companies, such as Neuralink, Facebook, and DARPA. These companies are developing some of the high-end Brain-Computer Interface technologies, and potentially, overall, such efforts will end up in digital longevity by the end of 2045.
The fifth speaker was Dr. Alex Zhavoronkov. Dr. Zhavoronkov is the founder of two companies, In Silico Medicine and Deep Longevity. In Silico Medicine is a venture-backed deep learning company focused on drug discovery and biomarker development for age-related diseases located at the Hong Kong Science and Technology Park, with over 100 bioinformatics and deep learning experts in six countries with four physical R&D sites. He and his team had built a sustainable revenue-generating model providing libraries of highly-promising pre-clinical leads to the pharmaceutical and biotechnology companies and collaborating with hundreds of research groups. Their main expertise is in the application of generative adversarial networks and reinforcement learning techniques for generating novel molecular structures and identifying promising targets for a variety of diseases, e.g. oncology/IO, fibrosis, dermatology, and senescence.
At Insilico Medicine, he, along with his team, invented and co-invented a range of aging and longevity biomarkers utilizing modern artificial intelligence techniques, published seminal papers, and filed for patents some of which were granted. They also discovered several mechanisms driving the aging process and invented interventions targeting these mechanisms. Deep Longevity was incubated by Insilico Medicine to commercialize these aging clocks further and help power the nascent longevity biotechnology industry.
Deep Longevity is developing explainable artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system, physiological, and psychological levels. It is also developing systems for the emerging field of longevity medicine, enabling physicians to make better decisions on the interventions that may slow down or reverse the aging processes. Deep Longevity developed Longevity as a Service (LaaS)© solution to integrate multiple deep biomarkers of aging dubbed “deep aging clocks” to provide a universal multifactorial measure of human biological age. Initially incubated by Insilico Medicine, Deep Longevity started its independent journey in 2020 after securing a round of funding from the most credible venture capitalists specializing in biotechnology, longevity, and artificial intelligence. ETP Ventures, Human Longevity and Performance Impact Venture Fund, BOLD Capital Partners, Longevity Vision Fund, LongeVC, co-founder of Oculus, Michael Antonov, and other experts AI and biotechnology investors supported the company. Deep Longevity established a research partnership with one of the most prominent longevity organizations, Human Longevity, Inc., to provide a range of aging clocks to the network of advanced physicians and researchers.
There was a panel discussion between Ilia Stambler, Sarah Ahamed, Alex Zhavoronkov, and Avinash K Singh together with the audience.
Tags: Conference, Event, Longevity, Longevity Day
